Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Assets (2017 - 2025)

Historic Return on Assets for Spero Therapeutics (SPRO) over the last 9 years, with Q3 2025 value amounting to 0.75%.

  • Spero Therapeutics' Return on Assets fell 7900.0% to 0.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75%, marking a year-over-year decrease of 7900.0%. This contributed to the annual value of 0.47% for FY2024, which is 6400.0% down from last year.
  • As of Q3 2025, Spero Therapeutics' Return on Assets stood at 0.75%, which was down 7900.0% from 0.77% recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Return on Assets registered a high of 0.18% during Q4 2023, and its lowest value of 1.49% during Q3 2022.
  • Its 5-year average for Return on Assets is 0.44%, with a median of 0.56% in 2021.
  • Its Return on Assets has fluctuated over the past 5 years, first skyrocketed by 14800bps in 2023, then plummeted by -9000bps in 2025.
  • Over the past 5 years, Spero Therapeutics' Return on Assets (Quarter) stood at 0.56% in 2021, then grew by 23bps to 0.43% in 2022, then soared by 143bps to 0.18% in 2023, then plummeted by -402bps to 0.56% in 2024, then tumbled by -34bps to 0.75% in 2025.
  • Its Return on Assets was 0.75% in Q3 2025, compared to 0.77% in Q2 2025 and 0.74% in Q1 2025.